Compounds > (4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone
Page last updated: 2024-12-08

(4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

(4-Methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone is a synthetic compound that is a **potent inhibitor of the enzyme tyrosine kinase**.

**Here's why it's important for research:**

* **Tyrosine kinases** are a family of enzymes that play a crucial role in cell signaling pathways. They are involved in regulating processes such as cell growth, differentiation, and survival.
* **Abnormal tyrosine kinase activity** is often implicated in the development of various cancers and other diseases.
* **Inhibitors of tyrosine kinases** can be used as potential therapeutic agents for the treatment of these diseases.

**(4-Methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone, specifically, exhibits significant inhibitory activity against:**

* **ABL kinase:** A tyrosine kinase associated with chronic myeloid leukemia.
* **Src kinase:** A tyrosine kinase involved in various cellular processes, including cell proliferation and migration, and linked to cancer development.

This makes it a **valuable tool for studying the role of tyrosine kinases in various diseases and for developing new drug therapies.**

**Note:** This compound is a research tool and is not currently used in clinical settings. Further research is needed to evaluate its potential therapeutic applications and safety profile.

(4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone: a tubulin inhibitor with antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID368149
CHEMBL ID431388
SCHEMBL ID9189645
MeSH IDM0560569

Synonyms (15)

Synonym
CHEMBL431388
nsc-638498
3,4',5-tetramethoxybenzophenone
nsc638498
NEURO_000297
NCI60_012883
(4-methoxyphenyl)-(3,4,5-trimethoxyphenyl)methanone
(4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone
methanone, (4-methoxyphenyl)(3,4,5-trimethoxyphenyl)-
109091-08-9
3,4,4',5-tetramethoxybenzophenone
GGZQGMKOFKNKQN-UHFFFAOYSA-N
SCHEMBL9189645
DTXSID80327242
(4-methoxy-phenyl)-(3,4,5-trimethoxy-phenyl)-methanone
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID420699Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
A diaryl sulfide, sulfoxide, and sulfone bearing structural similarities to combretastatin A-4.
AID450674Cytotoxicity against human A549 cells after 72 hrs by XTT assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Isocombretastatins A: 1,1-diarylethenes as potent inhibitors of tubulin polymerization and cytotoxic compounds.
AID53777Cell growth inhibition against DLD-1 human colon cancer cells using MTS assay2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents.
AID450669Inhibition of calf brain tubulin polymerization at 20 uM after 20 mins by turbidimetric method2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Isocombretastatins A: 1,1-diarylethenes as potent inhibitors of tubulin polymerization and cytotoxic compounds.
AID221812Cytotoxicity against human HT-29 colon cell line.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents.
AID103367Cytotoxicity against human MCF-7 breast cancer cell line.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents.
AID420702Displacement of [3H]colchicine from bovine brain tubulin at 50 uM by scintillation counting2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
A diaryl sulfide, sulfoxide, and sulfone bearing structural similarities to combretastatin A-4.
AID146719Cell growth inhibition against NUGC3 human stomach cancer cells using MTS assay2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents.
AID106340Cell growth inhibition against,MES-SA/DX5 human uterine cancer cells using MTS assay2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents.
AID79469Cell growth inhibition against HA22T human liver cancer cells using MTS assay2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents.
AID221796Compound was evaluated for cytotoxicity against human A-549 non-small cell lung cancer cell line.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents.
AID450675Cytotoxicity against human HeLa cells after 72 hrs by XTT assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Isocombretastatins A: 1,1-diarylethenes as potent inhibitors of tubulin polymerization and cytotoxic compounds.
AID450676Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Isocombretastatins A: 1,1-diarylethenes as potent inhibitors of tubulin polymerization and cytotoxic compounds.
AID103224Cell growth inhibition against MCF-7 human breast cancer cells using MTS assay2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents.
AID84539Cell growth inhibition against HR, human gastric cancer cells using MTS assay2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents.
AID90853Cell growth inhibition against Hone-1 human NPC cancer cells using MTS assay2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents.
AID57710Cell growth inhibition against DU-145 human prostate cancer cells using MTS assay2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents.
AID221950Cytotoxicity against human MLM melanoma cell line.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents.
AID106321Cell growth inhibition against MES-SA human uterine cancer cells using MTS assay2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents.
AID221962Compound was evaluated for cytotoxicity against human SKMEL-5 melanoma cell line.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents.
AID420703Inhibition of bovine brain tubulin by spectrophotometry2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
A diaryl sulfide, sulfoxide, and sulfone bearing structural similarities to combretastatin A-4.
AID228455Inhibition of tubulin polymerization1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents.
AID450673Cytotoxicity against human HL60 cells after 72 hrs by XTT assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Isocombretastatins A: 1,1-diarylethenes as potent inhibitors of tubulin polymerization and cytotoxic compounds.
AID420701Displacement of [3H]colchicine from bovine brain tubulin at 5 uM by scintillation counting2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
A diaryl sulfide, sulfoxide, and sulfone bearing structural similarities to combretastatin A-4.
AID52490Cell growth inhibition against colo 205 human colon cancer cells using tetrazolium dye reduction (MTS) assay2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's3 (42.86)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.72 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
dimethyl sulfoxide
Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.		2.0110sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.0610nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
bromodeoxyuridine
Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.		2.0810pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
thiazoles
[no description available]		2.08101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
thiazolyl blue
thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.		2.0810organic bromide saltcolorimetric reagent;
dye
erianin
Erianin: from Dendrobium chrysotoxum; structure in first source		2.0510
fosbretabulin
[no description available]		2.730stilbenoid
3,4',5-trimethoxystilbene
3,4',5-trimethoxystilbene: structure in first source		1.9810
dmu-212
[no description available]		2.0510
1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene
[no description available]		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		01.9810
Cancer of Colon
[description not available]		01.9810
Cancer of Lung
[description not available]		01.9810
Malignant Melanoma
[description not available]		01.9810
Breast Neoplasms
Tumors or cancer of the human BREAST.		01.9810
Colonic Neoplasms
Tumors or cancer of the COLON.		01.9810
Lung Neoplasms
Tumors or cancer of the LUNG.		01.9810
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		01.9810
Extravascular Hemolysis
[description not available]		02.0610
Hemolysis
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.		02.0610
Abnormalities, Autosome
[description not available]		02.0610